Nanobiotix S.A is a biotechnology business based in the US. Nanobiotix S-A shares (NBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Nanobiotix S-A employs 98 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Nanobiotix S-A
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NBTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Nanobiotix S-A stock price (NASDAQ: NBTX)Use our graph to track the performance of NBTX stocks over time.
Nanobiotix S-A shares at a glance
|Latest market close||$12.93|
|52-week range||$10.51 - $21.55|
|50-day moving average||$12.22|
|200-day moving average||$14.25|
|Wall St. target price||$27.04|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.66|
Buy Nanobiotix S-A shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Nanobiotix S-A stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Nanobiotix S-A price performance over time
|1 week (2021-10-14)||4.37%|
|1 month (2021-09-22)||7.67%|
|3 months (2021-07-22)||-7.30%|
|6 months (2021-04-22)||-17.37%|
|1 year (2020-10-18)||N/A|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
Nanobiotix S-A financials
|Revenue TTM||$2.4 million|
|Gross profit TTM||$2.5 million|
|Return on assets TTM||-31.43%|
|Return on equity TTM||-451.54%|
|Market capitalisation||$446.5 million|
TTM: trailing 12 months
Shorting Nanobiotix S-A shares
There are currently 11,274 Nanobiotix S-A shares held short by investors – that's known as Nanobiotix S-A's "short interest". This figure is 12.1% down from 12,828 last month.
There are a few different ways that this level of interest in shorting Nanobiotix S-A shares can be evaluated.
Nanobiotix S-A's "short interest ratio" (SIR)
Nanobiotix S-A's "short interest ratio" (SIR) is the quantity of Nanobiotix S-A shares currently shorted divided by the average quantity of Nanobiotix S-A shares traded daily (recently around 2057.299270073). Nanobiotix S-A's SIR currently stands at 5.48. In other words for every 100,000 Nanobiotix S-A shares traded daily on the market, roughly 5480 shares are currently held short.
To gain some more context, you can compare Nanobiotix S-A's short interest ratio against those of similar companies.
However Nanobiotix S-A's short interest can also be evaluated against the total number of Nanobiotix S-A shares, or, against the total number of tradable Nanobiotix S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nanobiotix S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Nanobiotix S-A shares in existence, roughly 0 shares are currently held short) or 0.0004% of the tradable shares (for every 100,000 tradable Nanobiotix S-A shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nanobiotix S-A.
Find out more about how you can short Nanobiotix S-A stock.
Nanobiotix S-A share dividends
We're not expecting Nanobiotix S-A to pay a dividend over the next 12 months.
Nanobiotix S-A share price volatility
Over the last 12 months, Nanobiotix S-A's shares have ranged in value from as little as $10.51 up to $21.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nanobiotix S-A's is 2.2847. This would suggest that Nanobiotix S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Nanobiotix S-A's beta into context you can compare it against those of similar companies.
- Moderna (MRNA.US): 1.4941
- Arrowhead Pharmaceuticals (ARWR.US): 1.2608
- Regulus Therapeutics (RGLS.US): 2.1974
Nanobiotix S-A overview
Nanobiotix S. A. , a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S. A.
Nanobiotix S-A in the news
NANOBIOTIX Provides Third Quarter Operational and Financial Update
NANOBIOTIX Provides Third Quarter Operational and Financial Update
Nanobiotix reports Q3 cash position of EUR89.8M
Frequently asked questionsWhat percentage of Nanobiotix S-A is owned by institutions?
Currently 13.938% of Nanobiotix S-A shares are held by institutions. How many people work for Nanobiotix S-A?
Latest data suggests 98 work at Nanobiotix S-A. When does the fiscal year end for Nanobiotix S-A?
Nanobiotix S-A's fiscal year ends in December. Where is Nanobiotix S-A based?
Nanobiotix S-A's address is: 60 rue de Wattignies, Paris, France, 75012 What is Nanobiotix S-A's ISIN number?
Nanobiotix S-A's international securities identification number is: US63009J1079
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert